For the year ending 2025-12-31, RPID had $3,038K increase in cash & cash equivalents over the period. -$31,912K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -47,123 |
| Depreciation and amortization expense | 3,252 |
| Noncash interest expense | 97 |
| Stock-based compensation expense | 4,033 |
| Provision for excess & obsolete inventory | 1,143 |
| Noncash lease expense | 1,218 |
| Gain on revaluation of warrant liability | -131 |
| Accretion on investments | -351 |
| Other | -34 |
| Accounts receivable | -4,387 |
| Inventory | -1,465 |
| Prepaid expenses and other current assets | -320 |
| Other long-term assets | -64 |
| Accounts payable | 1,600 |
| Accrued expenses and other current liabilities | 28 |
| Other long-term liabilities | 64 |
| Deferred revenue | -1,864 |
| Net cash used in operating activities | -31,062 |
| Purchases of property and equipment | 850 |
| Purchases of investments | 27,076 |
| Sales of investments | 2,505 |
| Maturity of investments | 39,750 |
| Net cash provided by investing activities | 14,329 |
| Proceeds from issuance of class a common stock - stock option exercise | 491 |
| Proceeds from issuance of class a common stock - employee stock purchase plan | 162 |
| Proceeds from issuance of debt | 20,000 |
| Payments of debt issuance costs | 878 |
| Issuance of class a common stock under the atm offering | 445 |
| Tax withholding on settlement of restricted stock units | 419 |
| Payments on finance lease obligations | 30 |
| Net cash provided by financing activities | 19,771 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 3,038 |
| Cash, cash equivalents and restricted cash at beginning of period | 17,276 |
| Cash, cash equivalents and restricted cash at end of period | 20,314 |
RAPID MICRO BIOSYSTEMS, INC. (RPID)
RAPID MICRO BIOSYSTEMS, INC. (RPID)